Please login to the form below

Not currently logged in


This page shows the latest Skyrizi news and features for those working in and with pharma, biotech and healthcare.

Lilly reports positive data from its phase 3 ulcerative colitis trial

Lilly reports positive data from its phase 3 ulcerative colitis trial

For Crohn’s, mirikizumab is in a close race with AbbVie’s IL-23 inhibitor Skyrizi (risankizumab), which recently met both primary endpoints of clinical remission and endoscopic response at week ... Skyrizi is also being evaluated in a phase 2/3 trial

Latest news

More from news
Approximately 8 fully matching, plus 18 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company Events and Exhibition Stands is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....